Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR OSTEOARTHRITIS THERAPEUTICS MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE OSTEOARTHRITIS THERAPEUTICS MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE OSTEOARTHRITIS THERAPEUTICS MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE OSTEOARTHRITIS THERAPEUTICS MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR OSTEOARTHRITIS THERAPEUTICS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.1 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY
15.1 OVERVIEW
15.2 KNEE
15.3 HIP
15.4 HAND
15.5 SMALL JOINTS (FOOT & ANKLE AND WRIST )
15.6 OTHERS
16 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY TYPE
16.1 (MARKET VALUE , VOLUME AND AVERAGE SELLING PRICE FOR EACH SUBSEGMENT OF THIS SEGMENT WILL BE PROVIDED)
16.2 OVERVIEW
16.3 MEDICATION
16.3.1 MARKETED DRUGS
16.3.1.1. ANALGESICS
16.3.1.1.1. ACETAMINOPHEN
16.3.1.1.2. OPIOIDS
16.3.1.1.2.1 CO-CODAMOL
16.3.1.1.2.2 OXYCODONE
16.3.1.1.2.3 TRAMADOL
16.3.1.1.2.4 PROPOXYPHENE
16.3.1.1.2.5 OTHERS
16.3.1.2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
16.3.1.2.1. CELECOXIB
16.3.1.2.2. PIROXICAM
16.3.1.2.3. IBUPROFEN
16.3.1.2.4. NAPROXEN
16.3.1.2.5. DICLOFENAC
16.3.1.2.5.1 PARENTERAL
16.3.1.2.5.2 ORAL
16.3.1.2.5.2.1. 50 MG
16.3.1.2.5.2.2. 75 MG
16.3.1.2.5.2.3. 100 MG
16.3.1.2.5.2.4. OTHERS
16.3.1.2.5.3 TOPICAL
16.3.1.2.5.3.1. 1.5% TOPICAL
16.3.1.2.5.3.2. 2% TOPICAL
16.3.1.2.5.3.3. OTHERS
16.3.1.2.6. DULOXETINE
16.3.1.2.7. ASPIRIN
16.3.1.2.8. OTHERS
16.3.1.3. COUNTERIRRITANTS
16.3.1.3.1. MENTHOL
16.3.1.3.2. LIDOCAINE
16.3.1.3.3. OTHERS
16.3.1.4. CALCIUM CHANNEL BLOCKER/COX-2 INHIBITOR COMBINATION
16.3.1.4.1. CELECOXIB/AMLODIPINE
16.3.1.4.2. CONSENSI
16.3.1.4.3. OTHERS
16.3.1.5. ANTIDEPRESSANTS
16.3.1.5.1. DULOXETINE
16.3.1.5.2. CYMBALTA
16.3.1.5.3. OTHERS
16.3.1.6. ANALGESIC
16.3.1.6.1. CAPSAICIN
16.3.1.6.2. QUTENZA
16.3.1.6.3. OTHERS
16.3.1.7. CORTICOSTEROIDS/ TRIAMCINOLONE ACETONIDE
16.3.1.7.1. METHYLPREDNISOLONE
16.3.1.7.2. KENALOG 40
16.3.1.7.3. ZILRETTA
16.3.1.7.4. BETAMETHASONE
16.3.1.7.5. OTHERS
16.3.1.8. ANTIRRHEUMATIC
16.3.1.8.1. EUFLEXXA
16.3.1.8.2. HYALGAN
16.3.1.8.3. ORTHOVISC
16.3.1.8.4. SUPARTZ
16.3.1.8.5. SYNVISC
16.3.1.8.6. SYNVISC-ONE
16.3.1.9. SKELETAL MUSCLE RELAXANTS
16.3.1.9.1. CARISOPRODOL
16.3.1.9.2. DANTROLENE
16.3.1.9.3. BACLOFEN
16.3.1.9.4. OTHERS
16.3.1.10. HYALURONIC ACID
16.3.1.11. PLATELET-RICH PLASMA (PRP)
16.3.1.12. OTHERS
16.3.2 PIPELINE DRUGS
16.3.2.1. APC201
16.3.2.2. GNSC-001
16.3.2.3. 4P004
16.3.2.4. DFV890
16.3.2.5. EP-104IAR
16.3.2.6. OTHERS
16.4 THERAPY
16.4.1 PHYSICAL THERAPY
16.4.2 OCCUPATIONAL THERAPY
16.4.3 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
16.4.4 OTHERS
16.5 SURGICAL PROCEDURES
16.5.1 BONE REALIGNMENT (OSTEOTOMY)
16.5.2 BONE FUSION (ARTHRODESIS)
16.5.3 JOINT REPLACEMENT SURGERY
16.5.4 ARTHROSCOPIC SURGERY
16.5.5 OTHERS
16.6 OTHERS
17 GLOBAL OSTEOARTHRITIS TREATMENT MEDICATION MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 EUFLEXXA
17.2.2 SUPARTZ FX
17.2.3 MONOVISC
17.2.4 ZILRETTA
17.2.5 NAPRELAN
17.2.6 DUEXIS
17.2.7 OTHERS
17.3 GENERICS
18 GLOBAL OSTEOARTHRITIS TREATMENT MEDICATION MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 TABLETS
18.2.2 CAPSULES
18.2.3 OTHERS
18.3 TOPICAL
18.3.1 CREAMS
18.3.2 GELS
18.3.3 SOLUTION
18.3.4 OTHERS
18.4 PARENTERAL
18.4.1 SUBCUTANEOUS
18.4.2 INTRA-ARTICULAR
18.4.3 OTHERS
18.5 OTHERS
19 GLOBAL OSTEOARTHRITIS TREATMENT MEDICATION MARKET, BY MODE OF PURCHASE
19.1 OVERVIEW
19.2 PRESCRIPTION
19.3 OVER THE COUNTER (OTC)
20 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY POPULATION TYPE
20.1 OVERVIEW
20.2 PEDIATRIC
20.3 ADULTS
20.4 GERIATRIC
21 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 BY TYPE
21.2.1.1. PUBLIC
21.2.1.2. PRIVATE
21.2.2 BY LEVEL
21.2.2.1. TIER 1
21.2.2.2. TIER 2
21.2.2.3. TIER 3
21.3 SPECIALTY CLINICS
21.4 HOME HEALTHCARE
21.5 AMBULATORY SURGICAL CENTERS
21.6 OTHERS
22 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDER
22.3 RETAIL SALES
22.3.1 ONLINE
22.3.1.1. E-STORES
22.3.1.2. COMPANY WEBSITE
22.3.1.3. OTHERS
22.3.2 OFFLINE
22.3.2.1. HOSPITAL PHARMACY
22.3.2.2. MEDICINE STORES
22.3.2.3. OTHERS
22.4 OTHERS
23 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 MERGERS & ACQUISITIONS
23.3 NEW PRODUCT DEVELOPMENT & APPROVALS
23.4 EXPANSIONS
23.5 REGULATORY CHANGES
23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY GEOGRAPHY
24.1 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1.1 NORTH AMERICA
24.1.1.1. U.S.
24.1.1.2. CANADA
24.1.1.3. MEXICO
24.1.2 EUROPE
24.1.2.1. GERMANY
24.1.2.2. FRANCE
24.1.2.3. U.K.
24.1.2.4. HUNGARY
24.1.2.5. LITHUANIA
24.1.2.6. AUSTRIA
24.1.2.7. IRELAND
24.1.2.8. NORWAY
24.1.2.9. POLAND
24.1.2.10. ITALY
24.1.2.11. SPAIN
24.1.2.12. RUSSIA
24.1.2.13. TURKEY
24.1.2.14. NETHERLANDS
24.1.2.15. SWITZERLAND
24.1.2.16. REST OF EUROPE
24.1.3 ASIA-PACIFIC
24.1.3.1. JAPAN
24.1.3.2. CHINA
24.1.3.3. SOUTH KOREA
24.1.3.4. INDIA
24.1.3.5. AUSTRALIA
24.1.3.6. SINGAPORE
24.1.3.7. THAILAND
24.1.3.8. MALAYSIA
24.1.3.9. INDONESIA
24.1.3.10. PHILIPPINES
24.1.3.11. VIETNAM
24.1.3.12. REST OF ASIA-PACIFIC
24.1.4 SOUTH AMERICA
24.1.4.1. BRAZIL
24.1.4.2. ARGENTINA
24.1.4.3. PERU
24.1.4.4. REST OF SOUTH AMERICA
24.1.5 MIDDLE EAST AND AFRICA
24.1.5.1. SOUTH AFRICA
24.1.5.2. SAUDI ARABIA
24.1.5.3. UAE
24.1.5.4. EGYPT
24.1.5.5. KUWAIT
24.1.5.6. ISRAEL
24.1.5.7. REST OF MIDDLE EAST AND AFRICA
24.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
26 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, COMPANY PROFILE
26.1 MARKETED DRUG MANUFRACTURE
26.1.1 FERRING B.V.
26.1.1.1. COMPANY OVERVIEW
26.1.1.2. REVENUE ANALYSIS
26.1.1.3. GEOGRAPHIC PRESENCE
26.1.1.4. PRODUCT PORTFOLIO
26.1.1.5. RECENT DEVELOPMENTS
26.1.2 BIOVENTUS
26.1.2.1. COMPANY OVERVIEW
26.1.2.2. REVENUE ANALYSIS
26.1.2.3. GEOGRAPHIC PRESENCE
26.1.2.4. PRODUCT PORTFOLIO
26.1.2.5. RECENT DEVELOPMENTS
26.1.3 SANOFI-AVENTIS U.S. LLC, A SANOFI COMPANY
26.1.3.1. COMPANY OVERVIEW
26.1.3.2. REVENUE ANALYSIS
26.1.3.3. GEOGRAPHIC PRESENCE
26.1.3.4. PRODUCT PORTFOLIO
26.1.3.5. RECENT DEVELOPMENTS
26.1.4 FIDIA PHARMA USA INC.
26.1.4.1. COMPANY OVERVIEW
26.1.4.2. REVENUE ANALYSIS
26.1.4.3. GEOGRAPHIC PRESENCE
26.1.4.4. PRODUCT PORTFOLIO
26.1.4.5. RECENT DEVELOPMENTS
26.1.5 ANIKA THERAPEUTICS, INC.
26.1.5.1. COMPANY OVERVIEW
26.1.5.2. REVENUE ANALYSIS
26.1.5.3. GEOGRAPHIC PRESENCE
26.1.5.4. PRODUCT PORTFOLIO
26.1.5.5. RECENT DEVELOPMENTS
26.1.6 PFIZER INC.
26.1.6.1. COMPANY OVERVIEW
26.1.6.2. REVENUE ANALYSIS
26.1.6.3. GEOGRAPHIC PRESENCE
26.1.6.4. PRODUCT PORTFOLIO
26.1.6.5. RECENT DEVELOPMENTS
26.1.7 PERRIGO COMPANY PLC.
26.1.7.1. COMPANY OVERVIEW
26.1.7.2. REVENUE ANALYSIS
26.1.7.3. GEOGRAPHIC PRESENCE
26.1.7.4. PRODUCT PORTFOLIO
26.1.7.5. RECENT DEVELOPMENTS
26.1.8 TAJ PHARMA GROUP
26.1.8.1. COMPANY OVERVIEW
26.1.8.2. REVENUE ANALYSIS
26.1.8.3. GEOGRAPHIC PRESENCE
26.1.8.4. PRODUCT PORTFOLIO
26.1.8.5. RECENT DEVELOPMENTS
26.1.9 WELLONA PHARMA
26.1.9.1. COMPANY OVERVIEW
26.1.9.2. REVENUE ANALYSIS
26.1.9.3. GEOGRAPHIC PRESENCE
26.1.9.4. PRODUCT PORTFOLIO
26.1.9.5. RECENT DEVELOPMENTS
26.1.10 BASF CORPORATION
26.1.10.1. COMPANY OVERVIEW
26.1.10.2. REVENUE ANALYSIS
26.1.10.3. GEOGRAPHIC PRESENCE
26.1.10.4. PRODUCT PORTFOLIO
26.1.10.5. RECENT DEVELOPMENTS
26.1.11 ADVACARE PHARMA
26.1.11.1. COMPANY OVERVIEW
26.1.11.2. REVENUE ANALYSIS
26.1.11.3. GEOGRAPHIC PRESENCE
26.1.11.4. PRODUCT PORTFOLIO
26.1.11.5. RECENT DEVELOPMENTS
26.1.12 ZIMMER BIOMET
26.1.12.1. COMPANY OVERVIEW
26.1.12.2. REVENUE ANALYSIS
26.1.12.3. GEOGRAPHIC PRESENCE
26.1.12.4. PRODUCT PORTFOLIO
26.1.12.5. RECENT DEVELOPMENTS
26.1.13 SAPHNIX LIFE SCIENCES
26.1.13.1. COMPANY OVERVIEW
26.1.13.2. REVENUE ANALYSIS
26.1.13.3. GEOGRAPHIC PRESENCE
26.1.13.4. PRODUCT PORTFOLIO
26.1.13.5. RECENT DEVELOPMENTS
26.1.14 JANSSEN PHARMACEUTICALS, INC.
26.1.14.1. COMPANY OVERVIEW
26.1.14.2. REVENUE ANALYSIS
26.1.14.3. GEOGRAPHIC PRESENCE
26.1.14.4. PRODUCT PORTFOLIO
26.1.14.5. RECENT DEVELOPMENTS
26.1.15 AMNEAL PHARMACEUTICALS NY LLC
26.1.15.1. COMPANY OVERVIEW
26.1.15.2. REVENUE ANALYSIS
26.1.15.3. GEOGRAPHIC PRESENCE
26.1.15.4. PRODUCT PORTFOLIO
26.1.15.5. RECENT DEVELOPMENTS
26.1.16 APOTEX INC
26.1.16.1. COMPANY OVERVIEW
26.1.16.2. REVENUE ANALYSIS
26.1.16.3. GEOGRAPHIC PRESENCE
26.1.16.4. PRODUCT PORTFOLIO
26.1.16.5. RECENT DEVELOPMENTS
26.1.17 TEVA PHARMACEUTICALS USA, INC.
26.1.17.1. COMPANY OVERVIEW
26.1.17.2. REVENUE ANALYSIS
26.1.17.3. GEOGRAPHIC PRESENCE
26.1.17.4. PRODUCT PORTFOLIO
26.1.17.5. RECENT DEVELOPMENTS
26.1.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
26.1.18.1. COMPANY OVERVIEW
26.1.18.2. REVENUE ANALYSIS
26.1.18.3. GEOGRAPHIC PRESENCE
26.1.18.4. PRODUCT PORTFOLIO
26.1.18.5. RECENT DEVELOPMENTS
26.1.19 KOLON TISSUEGENE, INC.
26.1.19.1. COMPANY OVERVIEW
26.1.19.2. REVENUE ANALYSIS
26.1.19.3. GEOGRAPHIC PRESENCE
26.1.19.4. PRODUCT PORTFOLIO
26.1.19.5. RECENT DEVELOPMENTS
26.1.20 AMPIO PHARMACEUTICALS INC.
26.1.20.1. COMPANY OVERVIEW
26.1.20.2. REVENUE ANALYSIS
26.1.20.3. GEOGRAPHIC PRESENCE
26.1.20.4. PRODUCT PORTFOLIO
26.1.20.5. RECENT DEVELOPMENTS
26.1.21 REGENERON PHARMACEUTICALS INC
26.1.21.1. COMPANY OVERVIEW
26.1.21.2. REVENUE ANALYSIS
26.1.21.3. GEOGRAPHIC PRESENCE
26.1.21.4. PRODUCT PORTFOLIO
26.1.21.5. RECENT DEVELOPMENTS
26.1.22 SMITH & NEPHEW
26.1.22.1. COMPANY OVERVIEW
26.1.22.2. REVENUE ANALYSIS
26.1.22.3. GEOGRAPHIC PRESENCE
26.1.22.4. PRODUCT PORTFOLIO
26.1.22.5. RECENT DEVELOPMENTS
26.1.23 PURDUE PHARMACEUTICALS L.P.
26.1.23.1. COMPANY OVERVIEW
26.1.23.2. REVENUE ANALYSIS
26.1.23.3. GEOGRAPHIC PRESENCE
26.1.23.4. PRODUCT PORTFOLIO
26.1.23.5. RECENT DEVELOPMENTS
26.1.24 BAYER AG
26.1.24.1. COMPANY OVERVIEW
26.1.24.2. REVENUE ANALYSIS
26.1.24.3. GEOGRAPHIC PRESENCE
26.1.24.4. PRODUCT PORTFOLIO
26.1.24.5. RECENT DEVELOPMENTS
26.1.25 BRISTOL LABORATORIES LTD
26.1.25.1. COMPANY OVERVIEW
26.1.25.2. GEOGRAPHIC PRESENCE
26.1.25.3. PRODUCT PORTFOLIO
26.1.25.4. RECENT DEVELOPMENTS
26.1.26 NOVARTIS AG
26.1.26.1. COMPANY OVERVIEW
26.1.26.2. REVENUE ANALYSIS
26.1.26.3. GEOGRAPHIC PRESENCE
26.1.26.4. PRODUCT PORTFOLIO
26.1.26.5. RECENT DEVELOPMENTS
26.1.27 LUPIN PHARMACEUTICALS, INC.
26.1.27.1. COMPANY OVERVIEW
26.1.27.2. REVENUE ANALYSIS
26.1.27.3. GEOGRAPHIC PRESENCE
26.1.27.4. PRODUCT PORTFOLIO
26.1.27.5. RECENT DEVELOPMENTS
26.1.28 GSK PLC.
26.1.28.1. COMPANY OVERVIEW
26.1.28.2. REVENUE ANALYSIS
26.1.28.3. GEOGRAPHIC PRESENCE
26.1.28.4. PRODUCT PORTFOLIO
26.1.28.5. RECENT DEVELOPMENTS
26.2 PIPELINE DRUG MANUFRACTURES
26.2.1 GENASCENCE
26.2.1.1. COMPANY OVERVIEW
26.2.1.2. REVENUE ANALYSIS
26.2.1.3. GEOGRAPHIC PRESENCE
26.2.1.4. PRODUCT PORTFOLIO
26.2.1.5. RECENT DEVELOPMENTS
26.2.2 4P PHARMA
26.2.2.1. COMPANY OVERVIEW
26.2.2.2. REVENUE ANALYSIS
26.2.2.3. GEOGRAPHIC PRESENCE
26.2.2.4. PRODUCT PORTFOLIO
26.2.2.5. RECENT DEVELOPMENTS
26.2.3 NOVARTIS AG
26.2.3.1. COMPANY OVERVIEW
26.2.3.2. REVENUE ANALYSIS
26.2.3.3. GEOGRAPHIC PRESENCE
26.2.3.4. PRODUCT PORTFOLIO
26.2.3.5. RECENT DEVELOPMENTS
26.2.4 BIOSPLICE THERAPEUTICS, INC.
26.2.4.1. COMPANY OVERVIEW
26.2.4.2. REVENUE ANALYSIS
26.2.4.3. GEOGRAPHIC PRESENCE
26.2.4.4. PRODUCT PORTFOLIO
26.2.4.5. RECENT DEVELOPMENTS
26.2.5 EUPRAXIA PHARMACEUTICALS
26.2.5.1. COMPANY OVERVIEW
26.2.5.2. REVENUE ANALYSIS
26.2.5.3. GEOGRAPHIC PRESENCE
26.2.5.4. PRODUCT PORTFOLIO
26.2.5.5. RECENT DEVELOPMENTS
26.2.6 ANDROS PHARMACEUTICALS CO., LTD
26.2.6.1. COMPANY OVERVIEW
26.2.6.2. REVENUE ANALYSIS
26.2.6.3. GEOGRAPHIC PRESENCE
26.2.6.4. PRODUCT PORTFOLIO
26.2.6.5. RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
